Agenda
Applications for consideration at this meeting
- 1374.1 Subcutaneous implantable cardioverter defibrillator therapy for the prevention of sudden cardiac death
- 1570 PD-L1 (Programmed Death Ligand 1) immunohistochemistry (IHC) testing for access to atezolizumab as first line therapy for patients with locally advanced or metastatic triple-negative breast cancer (TNBC)
- 1599 Genomic testing for the diagnosis of heritable cardiomyopathies
- 1600 Genetic testing for heritable kidney disease (other than Alport syndrome)
- 1608 Amnion membrane (human tissue) for topical treatment of ophthalmic disorders (caused by disease and/or trauma), and wound dressings for skin burns and ulcers on the craniofacial area, torso, and limbs
- 1614 Magnetic resonance-guided focused ultrasound for the treatment of medically refractory essential tremor
- 1615 Transcatheter occlusion of the left atrial appendage for patients with non-valvular atrial fibrillation
- 1617 BRAF V600 testing to help determine eligibility for PBS access to Braftovi (encorafenib), in patients with metastatic colorectal cancer (Stage IV)
- 1618 Testing of tumour prostate tissue to detect BRCA1/2 pathogenic gene variants in men with metastatic castration-resistant prostate cancer to help determine eligibility for PBS olaparib
- 1620 Magnetic Resonance Image Guided Radiation Therapy
- 1635 Transcatheter aortic valve implantation via transfemoral delivery using the balloon-expandable valve system for patients at low risk for surgery
- 1652 Transcatheter aortic valve implantation via transfemoral delivery for patients at intermediate risk for surgery
- 1664 Improvements to the National Cervical Screening Program Self-Collection Policy
Related information
Committee: